Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Waldenström’s Macroglobulinemia (WM)

      Waldenström’s Macroglobulinemia (WM)

      June 17, 2024
      1 min read
      • WM is another rare type of non-Hodgkin lymphoma, affecting two types of B-cells: lymphoplasmacytoid cells and plasma cells.[12]
      • WM is characterised by having high levels of an antibody known as immunoglobulin M (IgM). The build up of this protein causes excessive blood thickening which effects the flow of blood, especially through smaller blood vessels.[13]
      • Incidence rates in Europe are approximately one case per 102,220 people per year (2020) and the median age at diagnosis is 72 years.[14]

      Read more here

      [1] B Cell Metabolism and Autophagy in Autoimmunity - PMC (nih.gov)
      [2]  WebMD. What is B-Cell Lymphoma: Available at: https://www.webmd.com/cancer/lymphoma/what-is-b-cell-lymphoma#1. Last accessed March 2024.

      [3] National Cancer Institute. Lymphoma-patient version. Available at: https://www.cancer.gov/types/lymphoma. Last accessed March 2024.

      [4] American Cancer Society. What is Chronic Lymphocytic Leukemia? Available at: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/what-is-cll.html. Last accessed March 2024.

      [5] Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013; 122(23): 3723-27234.

      [6] Chiorazzi M, et al. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.

      [7] Yang O. Trends in disease burden of chronic lymphocytic leukemia at the Global, regional, and national levels from 1990 to 2019, and projections until 2030: A population-based epidemiologic study. Frontiers in Oncology. 2022;12.doi.org/10.3389/fonc.2022.840616.

      [8] Eichhorst B, et al; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Jan;32(1):23-33.

      [9] Lymphoma Action. Mantle cell lymphoma. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/mantle-cell-lymphoma. Last accessed March 2024

      [10] Cancer Research UK. Mantle cell lymphoma. Available at: https://cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/mantle-cell. Last accessed March 2024.

      [11] Dreyling M. Newly diagnosed and relapsed mantle cell lymphoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2018; 28:iv62–iv71. https://doi.org/10.1093/annonc/mdx223.

      [12] American Cancer Society. What is Waldenstrom Macroglobulinemia? Available at: https://cancer.org/cancer/waldenstrom-macroglobulinemia/about/what-is-wm.html. Last accessed March 2024.

      [13] “Waldenström Macroglobulinemia - Symptoms, Causes, Treatment: Nord. National Organization for Rare Disorders. Available at: https://rarediseases.org/rare-diseases/waldenstroms-macroglobulinemia/. Last accessed March 2024

      [14] Orphanet: Waldenström Macroglobulinemia. Available at: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=33226. Last accessed March 2024.

      [15] Lymphoma Action. Diffuse Large B-Cell Lymphoma. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma. Last accessed March 2024.

      [16] Tilly H. Diffuse Large B-Cell Lymphoma (DLBCL): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology. 2015; 26: v116–v125. doi:10.1093/annonc/mdv304.

      [17] Smith A. Impact of Age and Socioeconomic Status on Treatment and Survival from Aggressive Lymphoma: A UK Population-Based Study of Diffuse Large B-Cell Lymphoma. Cancer Epidemiology. 2015; 39: 6:1103–1112. doi:10.1016/j.canep.2015.08.015.

      [18] Lymphoma Action. Follicular Lymphoma. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma. Last accessed March 2024.

      [19] Orphanet: Follicular Lymphoma. Available at: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=545#:~:text=Clinical%20description,are%20affected%20in%20rare%20cases. Last accessed March 2024.

      [20] Yosifov DY. From biology to therapy: the CLL success story. Hemasphere. 2019;3: e175.

      [21] Schieber M. Current overview and treatment of mantle cell lymphoma. F1000Res. 2018;7: F1000 Faculty Rev-1136. doi:10.12688/f1000research.14122.1

      [22] Pooja A. Updates in prognostication and treatment of Waldenström’s macroglobulinemia, Hematology/Oncology and Stem Cell Therapy. 2019; 12:4: 179-188. doi.org/10.1016/j.hemonc.2019.05.002. 

      [23] Cheson B D. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer Journal. 2021;11,68.

      [24] Velcade summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf. Last accessed: March 2024.

      [25] Johnson & Johnson. The next frontier of prostate cancer care. Available at: https://www.jnj.com/innovation/next-frontier-prostate-cancer-treatment. Last accessed: March 2024.

      [26] HEAL. Men Prostate Cancer. Available at: https://www.env-health.org/IMG/pdf/prostate_testical.pdf. Last accessed March 2024.

      [27] European Cancer Patient Coalition White Paper on Bladder Cancer 2016. Available at: https://ecpc.org/wp-content/uploads/2019/08/ECPC-White-Paper-Bladder-Cancer-EN-1.pdf. Last accessed March 2024.

      [28] Montazeri K. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020;13(1): 1-6.

      [29] Cancer.net. Lung cancer – non-small cell: statistics. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Last accessed March 2024.